Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter)

Dearnaley DP; Norman AR; Shahidi M

首页> 外文期刊>The Journal of Urology >Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter)

【24h】

Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter)

机译：回复：在新辅助环境中施用3个月的促黄体生成素的激素释放激素激动剂后，血清睾丸激素恢复正常的时间：给药时间表和新辅助研究注意事项的含义（字母）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Journal of Urology》 |1999年第1期|共1页
作者
Dearnaley DP; Norman AR; Shahidi M;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
Antineoplastic Agents; Hormonal; Goserelin; Leuprolide; Prostatic Neoplasms; 抗肿瘤药; 激素; 戈舍瑞林; 亮丙瑞林; 前列腺肿瘤; 睾酮;

机译：Antineoplastic Agents;Hormonal;Goserelin;Leuprolide;Prostatic Neoplasms;抗肿瘤药;激素;戈舍瑞林;亮丙瑞林;前列腺肿瘤;睾酮;
入库时间 2022-08-18 18:32:15

相似文献

外文文献
中文文献

1. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter) [J] . Dearnaley DP, Norman AR, Shahidi M The Journal of Urology . 1999,第1期

机译：回复：在新辅助环境中施用3个月的促黄体生成素的激素释放激素激动剂后，血清睾丸激素恢复正常的时间：给药时间表和新辅助研究注意事项的含义（字母）
2. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study [J] . T Koie, C Ohyama, H Yamamoto, Prostate Cancer and Prostatic Diseases . 2012,第4期

机译：新辅助黄体生成激素释放激素激动剂加小剂量雌莫司汀磷酸盐在高危前列腺癌中的安全性和有效性：前瞻性单臂研究
3. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. [J] . Kaku H, Saika T, Tsushima T, The Prostate . 2006,第4期

机译：前列腺癌患者长期停止黄体生成激素释放激素激动剂治疗后血清睾丸激素和黄体生成激素水平的时程。
4. Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl [O] . Norihito Soga, Takumi Kageyama, Yuji Ogura, 2016

机译：抗去势抵抗前列腺癌和血清睾丸激素水平≥20 ng / dl的患者从黄体激素释放激素激动剂转换为拮抗剂的临床效果
5. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study [O] . T Koie, C Ohyama, H Yamamoto, 2012

机译：Neoadjuvant叶氏素释放激素激素激动剂加上低剂量雌激素磷酸盐的安全性和有效性，高危前列腺癌：一项潜在的单臂研究

Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter)

著录项

相似文献

相关主题

期刊订阅